Oncology

Spatially resolved technology based on next-generation sequencing has the potential to benefit clinical practice and improve the prognosis for cancer patients.

Patients with lymphoma can be immunocompromised due to their disease, anti-cancer therapy, and concomitant immunosuppressive treatments, which make them more vulnerable to developing a COVID-19 infection.

Despite the limited data, prior research indicates there are no serious cannabis-related adverse effects in pediatric patients.

Technology and regulations can revolutionize drug manufacturing and ensure a stable supply of medications.

The supplemental biologics license application for amivantamab-vmjw (Rybrevant) is supported by data from the phase 3 PAPILLON trial, evaluating the efficacy and safety of the drug in combination with chemotherapy for those with non–small cell lung cancer.

The kinase inhibitor is already approved for patients who experienced recurrence following 1 or more lines of standard of care platinum-containing chemotherapy.

Luspatercept-aamt (Reblozyl) approved to treat adults with very low- to intermediate-risk myelodysplastic syndrome who may require regular red blood cell transfusions.

Investigators found that artificial intelligence chatbots did not consistently provide recommendations for cancer treatment that correspond with NCCN guidelines.

The research was aided by the Decipher Genomics Resource for Intelligent Discovery, which helped derive the gene signatures used during the analysis.

In the study, investigators incorporated data from electronic health records and social determinants of health into the model to determine the likelihood in delays when starting cancer therapy.

During the phase 1b/2 trials, CAR T-cell therapy demonstrated significant and clinical survival benefits.

Protection of T cells from tumor-induced suppression suggests potential for enhancing efficacy of therapies, with plans to initiate a phase 1/2 clinical trial in patients with advanced breast cancer.

The drug showed statistically significant and clinically meaningful efficacy results across key subgroups.

Patients with pancreatic cancer who took benzodiazepine lorazepam had a shorter progression-free survival than those who took benzodiazepine alprazolam.

This month, we spoke with Cassia Griswold, PharmD, a clinical oncology pharmacist at Mayo Clinic Arizona.

Pharmacists can offer valuable information about sunburn, sunscreen, and skin cancer screening and provide OTC recommendations on sunburn treatment and prevention.

Opportunities for an additional specialization in molecular pathology may be helpful to train professionals in the real-time interpretation of gene therapy test results.

Based on results from a trial of repotrectinib in patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer, the FDA accepted the New Drug Application and set a Prescription Drug User Fee Act goal date of November 27, 2023.

Annual NCODA Oncology Institute brings together leaders in industry to speak with leaders in clinical practice to discuss some of the commonalities and areas of opportunity to address challenges facing oncology professionals.

The combination regimen showed positive progression-free survival results among patients with HER2-positive breast cancer in the phase 3 HER2CLIMB-02 trial, but overall survival data have yet to mature.

Melphalan/hepatic delivery system (Hepzato Kit; Delcath Systems Inc) is currently the only liver-directed therapy approved by the FDA for the treatment of netastatic uveal melanoma and percutaneous hepatic perfusion.

Unexpectedly, a study found that more than 70% of cancer survivors were current drinkers, indicating the need for intervention and strategies to reduce harmful drinking habits.

New data have resulted in updated guidelines for neoadjuvant cemiplimab.

Session at NACDS Total Store Expo discusses how pharmacies can leverage their accessibility to decrease diet-related diseases through health and wellness.

Elranatamab-bcmm (Elrexfio; Pfizer) is a BCMA-CD3-targeted bispecific antibody approved for adults with relapsed or refractory multiple myeloma who were previously administered at least 4 lines of therapy that included a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Study authors note that additional research is necessary to confirm findings and identify biological pathways of associations between sweetened beverages and diseases of the liver.

Niraparib and abiraterone acetate (Akeega; Janssen Pharmaceutical Companies of Johnson & Johnson) is the first-and-only dual action tablet that combines a PARP inhibitor with abiraterone acetate administered with prednisone.

In the COLUMBUS study, the FDA requested that the investigators evaluate the contribution of binimetinib while maintaining the same dosage of encorafenib at 300 mg to confirm the benefits of the combination.